• Adi Zoref-Lorenz, Mona Yuklea, Guy Topaz, Michael B Jordan, and Martin Ellis.
• Hematology Institute, Meir Medical Center, Kfar Saba, Israel. adilorenz@gmail.com.
• J Gen Intern Med. 2022 May 1; 37 (6): 154215461542-1546.

AbstractHemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that may complicate hematologic malignancies. HLH and malignancies have common clinical features, and HLH diagnostic criteria (HLH-2004/Hscore) were not validated in this specific population. We describe a case of a 72-year-old patient with a history of chronic lymphocytic leukemia stable for over 10 years who presented with fever and cytopenia. After excluding infectious etiologies and the progression of her disease, HLH was diagnosed. The patient was treated with etoposide, dexamethasone, intravenous immunoglobulin, and rituximab. Despite initial clinical improvement, the patient deteriorated and developed pulmonary aspergillosis and CNS involvement that reflected uncontrolled HLH. The patient died 45 days after her presentation. An unusual feature of this case was that HLH was not triggered by infection, disease transformation, or treatment. This case emphasizes the challenges of differentiating the development of overwhelming HLH from other complications associated with hematologic malignancy.© 2022. The Author(s) under exclusive licence to Society of General Internal Medicine.

22 keywords...

hide…